Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10054297 | 0.82 | TP53 (0.37) | MGAMGAASIMGAM2TP53 | |
| SCHEMBL9200803 | 0.82 | GAA (0.38) | MGAMGAASIMGAM2HSD17B10 | |
| SCHEMBL17233403 | 0.80 | TSHR (0.46) | MGAMGAASIMGAM2TP53 | |
| SCHEMBL2855195 | 0.79 | CYP1A2 (0.39) | TSHR | |
| SCHEMBL15453370 | 0.78 | MGAM (0.48) | MGAMGAASIMGAM2TP53 | |
| SCHEMBL31180081 | 0.78 | TP53 (0.34) | MGAMGAASIMGAM2TP53 | |
| SCHEMBL25487122 | 0.74 | CYP2C19 (0.32) | — | |
| SCHEMBL8798449 | 0.74 | CYP2C19 (0.32) | — | |
| SCHEMBL13435347 | 0.74 | TSHR (0.40) | MGAMGAASIMGAM2TP53 | |
| SCHEMBL1484429 | 0.74 | TSHR (0.40) | MGAMGAASIMGAM2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114889-B1 | METHOD OF PREPARING MONTELUKAST AND INTERMEDIATES USED THEREIN | HANMI SCIENCE CO LTD (KR) | 2014-01-22 | — | — | EP | disclosed |
| CN-101921220-B | Pharmaceutical compositions for treating diseases with bone mass loss having EP4 agonist as the active ingredient | ONO PHARMACEUTICAL CO | 2013-05-22 | — | — | CN | disclosed |
| US-8426599-B2 | Method for preparation of Montelukast acid in ionic liquid medium | HANMI SCIENCE CO., LTD (KR) | 2013-04-23 | — | — | US | disclosed |
| EP-2195295-B1 | METHOD FOR THE PREPARATION OF MONTELUKAST ACID IN IONIC LIQUID MEDIUM | HANMI SCIENCE CO LTD (KR) | 2013-01-23 | — | — | EP | disclosed |
| US-20120202773-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| US-8217174-B2 | Method of preparing montelukast and intermediates used therein | HANMI HOLDINGS CO., LTD. (KR) | 2012-07-10 | — | — | US | disclosed |
| US-8207223-B2 | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| WO-2012020271-A1 | PROCESS FOR THE PREPARATION OF MONTELUKAST SODIUM | RICHTER GEDEON NYRT. (HU) | 2012-02-16 | — | — | WO | disclosed |
| US-20110105757-A1 | METHOD FOR PREPARATION OF MONTELUKAST ACID IN IONIC LIQUID MEDIUM | HANMI PHARM. CO., LTD. (KR) | 2011-05-05 | — | — | US | disclosed |
| CN-101921220-A | Treat the EP that contains with the bone mass loss diseases associated 4Agonist is as the pharmaceutical composition of activeconstituents | ONO PHARMACEUTICAL CO | 2010-12-22 | — | — | CN | disclosed |
| US-5856322-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, CARDIOVASCULAR DISORDERS | MERCK FROSST CANADA, INC. (CA) | 1999-01-05 | — | — | US | disclosed |
| EP-0480717-B1 | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA INC (CA) | 1998-04-15 | — | — | EP | disclosed |
| EP-0500360-B1 | Quinoline-containing ketoacids as leukotriene antagonists | MERCK FROSST CANADA INC (CA) | 1997-06-25 | — | — | EP | disclosed |
| US-5565473-A | USEFUL AS ANTI-ASTHMATIC, ANTI-ALLERGIC, ANTI-INFLAMMATORY AND CYTOPROTECTIVE AGENTS; MONTELUKAST AND ITS SODIUM SALT | MERCK FROSST CANADA, INC. (CA) | 1996-10-15 | — | — | US | disclosed |
| US-5428033-A | Useful as anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotecyive agents | MERCK FROSST CANADA, INC. (CA) | 1995-06-27 | — | — | US | disclosed |
| US-5270324-A | Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-12-14 | — | — | US | disclosed |
| US-5212180-A | Quinoline-containing ketoacids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-05-18 | — | — | US | disclosed |
| EP-0500360-A1 | Quinoline-containing ketoacids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-08-26 | — | — | EP | disclosed |
| EP-0480717-A1 | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-04-15 | — | — | EP | disclosed |
| EP-0480716-A1 | Saturated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202773-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT | PTGER4, PTGER1, PTGER2 | MGAM 3411/4885GAA 3466/4885SI 2520/4885 |
| US-20110105757-A1 | METHOD FOR PREPARATION OF MONTELUKAST ACID IN IONIC LIQUID MEDIUM | CYSLTR1, LTC4S, CYSLTR2 | MGAM 2466/4885GAA 3454/4885SI 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.